

CAUSAL INFERENCE PROJECT

With increasing data availability, treatment causal effects can be evaluated across different dataset, both randomized trials and observational studies. Randomized trials isolate the effect of the treatment from that of unwanted (confounding) co-occurring effects. But they may be applied to limited populations, and thus lack external validity. On the opposite large observational samples are often more representative of the target population but can conflate confounding effects with the treatment of interest. In this paper, we review the growing literature on methods for causal inference on combined randomized trial and observational studies, striving for the best of both worlds.

Randomized controlled trial

This section recalls assumptions and estimators for average treatment estimation in the case of a single RCT. The assumptions for average treatment effect identifiability in RCTs are the SUTVA assumption and assumptions 3.1 (consistency) and 3.2 (random treatment assignment within the RCT). These assumptions allow the average treatment effect to be identifiable. The most intuitive estimator coming from these assumptions is the difference-in-means estimator:

$$\begin{aligned} \tau^{\text{DM}} &= \frac{1}{n_1} \sum_{A_i=1} Y_i - \frac{1}{n_0} \sum_{A_i=0} Y_i \quad (\text{S1}) \end{aligned}$$

With n_1 being the number of individuals in the trial that have been treated and n_0 the number of individuals in the trial who have not been treated ($n_0 + n_1 = n$). This estimator is unbiased and \sqrt{n} -consistent if the sample selection is not moderated by the covariates. If not, it is a biased estimation

of the population average treatment effect.

Estimation of ATE in observational data

Let us recall the IPW estimator in the case of observational data:

$$\frac{1}{m} \sum_{i=1}^m A_i Y_i - \frac{1}{m} \sum_{i=1}^m (1 - A_i) Y_i = \frac{1}{m} \sum_{i=1}^m \frac{A_i Y_i}{e(X_i)} - \frac{1}{m} \sum_{i=1}^m \frac{(1 - A_i) Y_i}{1 - e(X_i)}, \quad (S2)$$

with $e(x) = P(A = 1 | X = x)$ the propensity score, i.e., the probability to be treated given the covariates.

The rationale of IPW is to upweight treated observations with a small propensity score (and the other way around) to balance the two groups, treated and non treated, with respect to their covariates.

Identification formula

This part focuses on the non-nested design only, as it corresponds to the central design of this review.

Identification by the g-formula or regression formula in the target population

Proof S1

$$E[Y(a)] = E[E[Y(a) | X]] \quad \text{Law of total expectation}$$

$$= E[E[Y(a) | X, S = 1]] \quad \text{Assump. 3.4}$$

$$= E[E[Y(a) | X, S = 1, A = a]] \quad \text{Assump. 3.4}$$

$$= E[E[Y | X, S = 1, A = a]] \quad \text{Assump. 3.1}$$

This last quantity can be expressed as a function of the distribution of X in the target population:

$$E[Y(a)] = \int E[Y | X = x, S = 1, A = a] df(x),$$

where $f(X)$ denotes the distribution of X in the target population.

Identification by weighting

Proof S2 $\tau = E [\tau (X)]$ Law of total expectation
 $= E [\tau 1(X)]$ Assump. 3.3
 $= E \sum_1 f(X) \tau(X) | S = 1$ Assump. 3.6.

$f(X | S = 1)$

Using Bayes' rule, we note that $P(S = 1)$ $P(S = 1)$

$f(x)$ $P(S = 1 | X = x) =$.

$=$ $\frac{\pi_S(x)}{P(S = 1)}$

$f(x | S = 1)$ _____

In this expression, however, it is important to notice that neither $\pi_S(x)$ nor $P(S = 1)$ can be estimated from the data, because we do not observe the S indicator in the observational study (Figure 1). On the other hand, the conditional odds ratio $\alpha(x)$ can be estimated by fitting a logistic regression model that discriminates RCT versus observational samples, and Bayes' rule gives:

$\alpha(x) = P(i \in R | \exists i \in R \cup O, X_i = x)$

$P(i \in O | \exists i \in R \cup O, X_i = x)$

$= P(i \in R) \times P(X_i = x | i \in R)$

$P(i \in O) \times P(X_i = x | i \in O)$

$= n \times f(x | S = 1),$

and therefore $m \times f(x)$

$$\tau = E \sum_{n} \tau(X) | S = 1 \Sigma .$$

This quantity can be further developed, underlying $\tau_1(X)$ identification as presented in proof S3.

Proof S3

$$\tau_1(x) = E [Y(1) - Y(0) | X = x, S = 1] \quad \text{Assump. 3.2}$$

$$= E [Y(1) | X = x, S = 1] - E [Y(0) | X = x, S = 1]$$

$$= E [A | X = x, S = 1] E [Y(1) | X = x, S = 1]$$

$$e_1(x)$$

$$E [1 - A | X = x, S = 1] E [Y(0) | X = x, S = 1] 1 - e_1(x)$$

$$= E [AY(1) | X = x, S = 1] - E [(1 - A)Y(0) | X = x, S = 1]$$

$$e_1(x) \quad 1 - e_1(x)$$

$$= E [AY | X = x, S = 1] - E [(1 - A)Y | X = x, S = 1] \quad \text{Assump. 3.1}$$

$$e_1(x) \quad 1 - e_1(x)$$

$$= E \sum A Y - 1 - A Y | X = x, S = 1 \Sigma .$$

$$e_1(x) \quad 1 - e_1(x)$$

Nested study design

The nested trial design has different impacts on the estimators expressions previously introduced, and even on the causal quantity of interest. In a nested trial design the randomized trial is embedded in a cohort (e.g. a large cohort - considered as a sample from the target population - in which eligible people are proposed to participate in the trial, but if they refuse they are still included in the cohort study). As a consequence, S is the binary indicator for trial participation, with $S = 1$ for participants and $S = 0$ for non-participants. Therefore the sampling probability of non-randomized individuals is known in nested trial designs (Buchanan et al., 2018; ?). Mathematically it means that the quantity $P(S = 1)$ is identifiable. In addition, two causal quantities can be identified: $E[Y(1) - Y(0)]$ and $E[Y(1) - Y(0) | S = 0]$. It is important to note that the second quantity can have a scientific interest in order to better understand heterogeneities within the cohort, and variables that influence the sampling selection and/or the treatment effect on the outcome.

When observational data have no outcome and treatment information

Main estimators, such as IPSW, g-formula, and doubly-robust estimators are presented for the specific case of nested trial design.

IPSW

In this design the weights in the IPSW estimators are different, because the quantity πS can be

estimated directly from the observed data as the indicator S is observed. This allows the IPSW formula to be closer to the classic IPW expression without the need to use the odds ratio to weigh data. The IPSW expression is the following:

$$\hat{\tau}^{IPSW-nested} = \frac{1}{n} \sum_{i=1}^n \frac{A_i Y_i}{\pi^S(X_i) e_1(X_i)} = \frac{1}{n} \sum_{i=1}^n \frac{(1 - A_i) Y_i}{\pi^S(X_i) (1 - e_1(X_i))}. \quad (S3)$$

The normalized version is the following one:

$$IPSW-nested\ norm. = \frac{\sum_{i=1}^n (\pi^S(X_i) e_1(X_i))^{-1} A_i Y_i}{\sum_{i=1}^n (\pi^S(X_i) (1 - e_1(X_i)))^{-1} (1 - A_i) Y_i} \quad (S4)$$

$$\hat{\tau} = \frac{\sum_{i=1}^n (\pi^S(X_i) e_1(X_i))^{-1} A_i Y_i}{\sum_{i=1}^n (\pi^S(X_i) (1 - e_1(X_i)))^{-1} (1 - A_i) Y_i}.$$

Proof S4

$$\tau = E[\tau(X)] \quad \text{Law of total expectation}$$

$$= E[\tau 1(X)] \quad \text{Assump. 3.3}$$

$$= E \sum_{s=1}^2 f(X) \tau(X) | S = 1 \sum_{s=1}^2 \text{Assump. 3.6}$$

$$f(X | S = 1) = \frac{\sum_{i=1}^n \tau(X_i) | S = 1}{P(S = 1)}$$

$$P(S = 1)$$

$$1$$

$$\pi^S(X) = \frac{1}{n} \sum_{i=1}^n \pi^S(X_i) | S = 1 \quad P(S = 1) = n \text{ in the nested design}$$

$$= E \sum_{i=1}^n \pi^S(X_i) | S = 1$$

Where π_S can be estimated directly using the randomized and the non randomized data. τ_1 is further derived as presented in proof S3.

G-formula

The g-formula formulation in the case of nested trial design depends on the causal quantity of interest. When the target population is the causal quantity of interest, then the identification expression is the same as in the non-nested design. But, because $f = f_{\cdot|S=0}$, the estimator's expression is slightly different:

$$\tau^{\wedge}_{g\text{-nested}} = \frac{1}{n+m} \sum_{i=1}^{n+m} (\mu^{\wedge}_{1,1}(X_i) - \mu^{\wedge}_{0,1}(X_i)), \quad (S5)$$

In the case where the population of interest is the non-randomized one, the identification of the causal quantity of interest is the following:

$$E[Y(a) | S = 0] = E[E[Y | X, S = 1, A = a] | S = 0] = E[\mu_{1,1}(X) - \mu_{0,1}(X) | S = 0] \quad (S6)$$

The Proof S5 details the calculus. And the estimator is the same as presented in equation 5 as the integration is done on the law $f_{\cdot|S=0}$.

Proof S5

$$\begin{aligned} E[Y(a)|S = 0] &= E[E[Y(a) | X]|S = 0] && \text{Law of total expectation} \\ &= E[E[Y(a) | X, S = 1]|S = 0] && \text{Assump. 3.4} \\ &= E[E[Y(a) | X, S = 1, A = a]|S = 0] && \text{Assump. 3.4} \\ &= E[E[Y | X, S = 1, A = a]|S = 0] && \text{Assump. 3.1} \end{aligned}$$

This last quantity can be expressed as a function of the distribution of X in the non-randomized

population:

$$E[Y(a)] = \int E[Y | X = x, S = 1, A = a] f(x|S = 0) dx$$

Combining treatment-effect estimates from both sources of data

Under Assumptions 3.1, 3.2 and 3.5 for the RCT and Assumptions 4.1 and 4.2 for the observational data, separate estimators of the ATEs from the two data sources can be constructed. ? considered the ATEs for the comprehensive cohort studies (CCS) which include participants who would like to be randomized, constituting the RCT, and participants who would like to choose the treatment by their preference, constituting the observational sample. In particular, they considered the ATE over the CCS study population τ_2 and the ATE over the trial population τ_1 . Note that τ_2 is different from τ in our setting because τ_2 is defined with respect to the combined RCT and observational sample; while τ is defined with respect to the observational sample only. In order to construct improved estimators by combining study-specific estimators, they derived the optimal influence functions for τ_1 and τ_2 , which suggest that the efficient estimators of τ_1 and τ_2 can be obtained by

$$\tau_{1,eff} = \frac{1}{n} \sum_{i=1}^{n+m} \pi^s(X_i) A_i Y_i - \frac{A \pi^s(X) \Sigma}{\theta(X_i)} + \frac{A \pi^s(X) \Sigma}{\theta(X_i)} \frac{\hat{\mu}_i(X_i)}{1 - \theta(X_i)}$$

where $e(X), \mu$

$$\tau^{\wedge} =$$

$$\sum A_i \{Y_i - \mu^1(X_i)\} - \mu^1(X),$$

$$- (1 - A_i) \{Y_i -$$

$\mu^0(X_i)\} + \{\mu^1(X) - \mu^0(X)\}$, and $\mu^1(X)$ for units in the RCT are simplified as $e(X)$, $\mu(X)$, and

$$2, \text{eff} = \frac{n + m}{n} \frac{\sum_{i=n} e^1(X_i) - 1 - e^0(X_i)}{1 - e^0(X_i)}$$

$$\mu^1(X_i) = \frac{e^1(X_i) - e^0(X_i)}{1 - e^0(X_i)}$$

$$\frac{e^1(X_i) - e^0(X_i)}{1 - e^0(X_i)}$$

$$1$$

Examples of implementations

This part follows Section 6 and proposes specific examples of implementations for the nested design in the case of IPSW and G-formula.

IPSW

The IPSW estimator can be implemented using the available code from Dahabreh et al. (2019). It requires as input a dataframe (here called study) which columns represent treatment, denoted by A (binary), the RCT indicator, denoted as S (binary), the outcome as Y (continuous), and the quantitative covariates. The current available code for 3 quantitative covariates denoted X1, X2, X3 is presented below. A first function generate_weights() estimates the sampling propensity score and the propensity score as logistic regressions, and compute the according weights to each data point. The variance is estimated with the geex library (Saul and Hudgens, 2020) through the m_estimate function which computes the empirical sandwich variance estimator.

```

1 # Compute selection score model and propensity score in the trial ( logit )
2 weights <- generate_weights ( Smod = S ~ X1 + X2 + X3 , Amod = A ~ X1 + X2 + X3 , study
)
3

```

```

4   # Use these scores to compute IPSW
5   IOW1 <- IOW1_est ( data = weights$ dat )
6
7   # Compute the empirical sandwich variance
8   param_start_IOW1 <- c( coef( weights$ Smod ), coef( weights$ Amod ),
9   m1 = IOW1$IOW1_1 , m0 = IOW1$IOW1_0 , ate = IOW1$IOW1 )
10  IOW1_mest <- m_estimate ( est_FUN = IOW1_EE , data = study ,
11  root_control = setup_root_control ( start = param_start_IOW1 ))
12
13  # Format the output
14  IOW1_ate <- extract_EST ( geex_output = IOW1_mest ,
15  est_name = " ate " ,
16  param_start = param_start_IOW1 )

```

The output is:

```

1   print ( IOW1_ate )
2   >   ate   SE
3   >   -0.16961   0.02751

```

G-formula

The G-formula can also be implemented in the nested design using the available code from Dahabreh et al. (2019). It takes a similar entry as the IPSW previously presented. The variance is estimated with the `geex` library (Saul and Hudgens, 2020) through the `m_estimate` function which computes the empirical sandwich variance estimator.

```
1   # Linear regression cond . outcome mean as a function of covariates on the RCT
2   # Compute ATE on the observational data
3   OM <- OM_est ( data = study )
4
5   # Compute the empirical sandwich variance
6   param_start_OM <- c( coef ( OM$ OM 1 mod ), coef ( OM$ OM 0 mod ),
7   m1 = OM$OM_1 , m0 = OM$OM_0 , ate = OM$ OM )
8   OM_mest <- m_estimate ( est FUN = OM_EE , data      = study ,
9   root_control = setup_root_control ( start = param_start_OM ))
10
11  # Format the output
12  OM_ate <- extract EST ( geex_output = OM_mest , est_name = " ate " ,
13  param_start = param_start_OM )
```

The output is:

```
1   >      ate      SE
```

Notations and Assumptions in the Structural Causal Model

Structural Causal Models (SCM). We define a structural causal model as a 3-tuple $M = (U, V, F)$ such that, U and V are sets of respectively unobserved and observed variables with distribution $P(U)$ and $P(V)$, and F is a set of functions f_1, \dots, f_n such that, for each $v_i \in V$, $v_i = f_i(\text{pai}, u_i)$, where $\text{pai} \subseteq V \setminus v_i$ and $u_i \in U$. The notation pai (denoted “parents” of v_i) represents the set of variables that directly determine the value of v_i . Such equations are called structural equations. For example, let us consider the following SCM M ,

$$a \leftarrow f_a(x, u_a),$$




Figure 15: Left: (a) example of an SCM M and corresponding DAG; right: (b) Post-intervention graph of M for

$\text{do}(A = a_0)$.

$$y \leftarrow f_y(a, x, u_y).$$

Often, neither parametric assumptions are made on f_a and f_y , nor distributional assumptions on random variables.

Interventions. At the core of the SCM framework is the do-operator which enables the use of structural equations to represent causal effects and counterfactuals. The $\text{do}(A = a_0)$ operation marks the replacements of the mechanism f_a with a constant a_0 , while keeping the rest of the model unchanged, resulting in the following post-treatment model:

$$a \leftarrow a_0$$

$$y \leftarrow f_y(a, x, u_y)$$

In the causal graph, this corresponds to deleting all incoming arrows in A (Figure 15(b)).

We denote $Q = P(Y = y \mid \text{do}(A = a_0))$ the post-intervention distribution, i.e., the distribution of a random variable Y after a manipulation on A . From this distribution, the ATE can be written as:

$$\begin{aligned} \tau &= E[Y \mid \text{do}(A = a_1)] - E[Y \mid \text{do}(A = a_0)] \\ &= \sum_y y(P\{y \mid \text{do}(a_1)\} - P\{y \mid \text{do}(a_0)\}). \end{aligned}$$

y

Note that the post-intervention distribution can also be denoted in counterfactual notation as $P(y \mid \text{do}(a)) = P(Y(a) = y)$. The distinction between $P(Y \mid A = a)$ and $P(Y \mid \text{do}(a))$ corresponds in the

potential outcomes framework to the difference between $P(Y | A = a)$ and $P(Y(a))$.

D-separation. Conditional independences between variables can be read from the DAG induced by an SCM using a graphical criterion known as d-separation. This criterion will be useful in identifying the causal effect.

Definition 2 (d-separation) A set X of nodes is said to block a path p if either p contains at least one arrow-emitting node that is in X , or p contains at least one collision node that is outside X and has no descendant in X .

If X blocks all paths from set A to set Y , it is said to “d-separate A and Y ” and then it can be shown that $A \perp\!\!\!\perp Y \mid X$. As an illustration, let us consider a path with $A \rightarrow D \leftarrow B \rightarrow C$. Since B emits arrows on that path, it blocks the path between A and C , and $A \perp\!\!\!\perp C \mid B$. D is a collider (two arrows incoming) and consequently it blocks the path without conditioning $A \perp\!\!\!\perp C$; but conditioning on D would open the path and thus would imply that $A \perp\!\!\!\perp C \mid D$.

Furthermore, in the SCM framework it is generally assumed that faithfulness holds, i.e., that all conditional independences are encoded in the graph, allowing to infer dependences from the graph structure (Peters et al., 2017). In other words, if the Global Markov property (i.e., d-separation implies conditional independence), and faithfulness hold, then the resulting equivalence between conditional independences and d-separation allows to move back and forth between the graphical and the probabilistic model.

Identifiability We are interested in answering the identifiability question: can the post-intervention distribution Q be estimated using observed data (such as pre-intervention distribution)?

Definition 3 (identifiability) A causal query Q is identifiable from distribution $P(y)$ compatible with

a causal graph G , if for any two (fully specified) models $M1$ and $M2$ that satisfy the assumptions in G , we have

$$P1(v) = P2(v) \implies Q(M1) = Q(M2).$$

Specifically, if a causal query Q in the form of a do-expression can be reduced to an expression no longer containing the do-operator (i.e, containing only estimable expressions using nonexperimental, observed data) by iteratively applying the inference rules of do-calculus, then Q is identifiable. The language of do-calculus is proved to be complete for queries in the form $Q = P(y \text{ do}(a), x)$ meaning that if no reduction can be obtained using these rules, Q is not identifiable.

The application of previous rules and the backdoor criterion in the graph of Figure 16 allows to list all possible admissible adjustment sets for identifying $P(y \mid \text{do}(a))$:

$$X = \{W2\}, \{W2, W3\}, \{W2, W4\}, \{W3, W4\}, \{W2, W3, W4\}, \{W2, W5\}, \{W2, W3, W5\}, \\ \{W4, W5\}, \{W2, W4, W5\}, \{W3, W4, W5\}, \{W2, W3, W4, W5\} \text{ (S7)}$$

The analyst can select from this list which is preferable. Note that conditioning on $W1$ would induce bias as it is a collider.

Proof of the transport formula (Theorem 5.2)

We compute:

$$P(y \mid \text{do}(a), S = s^*) = \int P(y \mid \text{do}(a), S = s^*, X = x)P(x \mid \text{do}(a), S = s^*) \\ \times \\ = \int P(y \mid \text{do}(a), X = x, S = s)P(x \mid \text{do}(a), S = s^*) \times$$

Figure 16: Application of the backdoor criterion in large graphs. Based on the admissible set definition 1, (S7) present all the following sets that are admissible and can be used for adjustment. For example, the set $\{W2, W3\}$ blocks all backdoor paths between A and Y . W2 block the path $A \leftarrow W2 \rightarrow W3 \rightarrow W5 \rightarrow Y$.

$$= \sum P(y | do(a), X = x, S = s) P(x | S = s^*) .x$$

The first equation follows by conditioning. The second line is derived by using the s-admissibility of X. The third line results from the fact that A is a child of X and, therefore, exerts no causal influence on X.

Additional simulation results

This section follows Section 6.3 and provides additional results for the simulations.

Distributional shift between RCT and observational samples

The simulation design proposed simulates a situation where the RCT data reveals a distributional shift with the observational sample. In the RCT all the covariates tend to have lower values than in the observational sample. Still, the overlap assumption (Assumption 4.2) is still valid as each individu in the target population has a non-zero probability to be included in the experimental sample. Quantitative results obtained for a simulation with 1000 observations in the RCT and 10 000 observations in the observational sample is given on Figure 17, in addition with an histogram illustrating overlaps and the distributional shift for the covariate X1.

Stratification

Within the weighted estimators, the stratification estimator (Section 3.2.1) supposes to choose an additional parameter being the number of strata used. Simulations are launched with the number of strata varying from 3 to 15, and the results are presented on Figure 18. We observed that the number of strata has an impact on the results, the higher the number of strata used, the better the prediction.




Figure 17: Covariates distributions differences between experimental sample and observational sample when simulating according to (15) as detailed in Section 6.3 (left), with a focus on the X1 distributional shift with histograms overlap for the two samples (right).




Figure 18: Effect of strata number Estimated ATE obtained while varying the number of strata L 3, 5, 7, 9, 11, 13, 15 with 100 repetitions each time. All other simulation parameters being the same as the standard case described in 6.3 and in Figure 6. the corresponding sample sizes).

This issue does not apply to the complementary stratum of severe TBI patients (corresponding to a low Glasgow score (GCS 8)). We can thus provide the results for this stratum in Figure 30. We observe that on this strata discrepancies between the solely Traumabase estimators and the generalized estimators are presents. The generalization supports either no-effect or a deleterious effect, while the RCT and the observational estimators support the no-effect hypothesis.

We model each patient in the RCT or observational population as described by a random tuple $(X, Y(0), Y(1), A, S)$ drawn from a distribution, where X is a p -dimensional vector of covariates, A denotes the binary treatment assignment (with $A = 0$ for the control and $A = 1$ for the treated patients), $Y(a)$ is the binary or continuous outcome had the subject been given treatment a (for $a \in \{0, 1\}$), and S is a binary indicator for RCT eligibility (i.e., meet the RCT inclusion and exclusion criteria) and willingness to participate if being invited to the trial ($S = 1$ if eligible and also willing to participate if being invited to the trial, $S = 0$ if not).

Assuming consistency of potential outcomes, we also denote by $Y = AY(1) + (1 - A)Y(0)$ the

outcome realized under treatment A. We model the patients belonging to an RCT sample of size n and in an observational data sample of size m by $n + m$ independent random tuples:

$\{X_i, Y_i(0), Y_i(1), A_i, S_i\}_{i=1}^{n+m}$, where the RCT samples $i = 1, \dots, n$ are identically distributed ac-

1Note that S takes several acceptations depending on research papers, for example other works use two indicators,

one for participation and one for eligibility (Nguyen et al., 2018; Dahabreh et al., 2019). In such situations $S = 1$ denotes eligible and participating to the trial people, while $S = 0$ denotes ineligible or eligible but necessarily non-participating people

According to $(X, Y(0), Y(1), A, S \mid S = 1)$, and the observational data samples $i = n + 1, \dots, n + m$ are identically distributed according to $(X, Y(0), Y(1), A, S)$. For simplicity of exposition, we also denote $\mathcal{I}^R = 1, \dots, n$ the index set of units observed in the RCT study, and $\mathcal{I}^O = n+1, \dots, n+m$ the index set of units observed in the observational study.

For each RCT sample i , we observe $(X_i, A_i, Y_i, S_i = 1)$, while for observational data i , we consider two settings:

We only observe the covariates X_i ,

We also observe the treatment and outcome (X_i, A_i, Y_i) .

The former case will be discussed in the next section while the latter will be detailed in Section 4. We define the conditional average treatment effect (CATE):

$$\tau(x) = E[Y(1) - Y(0) \mid X = x],$$

and the population average treatment effect (ATE):

$$\tau = E[Y(1) - Y(0)] = E[\tau(X)].$$

We note that in general, if the samples in the RCT and observational data do not follow the same distribution, then the ATE is different from the RCT (or sample) average treatment effect

$$\tau \neq \tau^1, \quad \tau^1 = E[Y(1) - Y(0) \mid S = 1].$$

We denote respectively by $e(x)$ and $e^1(x)$ the propensity score in the observational data and in the RCT population:

$$e(x) = P(A = 1 \mid X = x), \quad e^1(x) = P(A = 1 \mid X = x, S = 1).$$

We also denote by $\mu_a(x)$ and $\mu_{a,1}(x)$ the conditional mean outcome under treatment $a \in \{0, 1\}$ in the

observational data and in the RCT population, respectively:

$$\mu_{a,0}(x) = E [Y(a) | X = x], \quad \mu_{a,1}(x) = E [Y(a) | X = x, S = 1],$$

and by $\pi_S(x)$ the selection score²:

$$\pi_S(x) = P(S = 1 | X = x).$$

Note that $\pi_S(x)$ is the probability of being eligible for selection in the RCT given covariates x . It is different from the probability that an individual with covariates x known to be in the study (RCT or observational population) is selected in the RCT:

$$\pi_S(x) \neq \pi_R(x), \quad \pi_R(x) = P(\exists i \in R, X_i = x | \exists i \in R \cup O, X_i = x).$$

We similarly note

$$\pi_O(x) = P(\exists i \in O, X_i = x | \exists i \in R \cup O, X_i = x) = 1 - \pi_R(x).$$

Finally, we denote by $\alpha(x)$ the conditional odds ratio that an individual with covariates x is in the RCT or in the observational cohort:

$$\alpha(x) = P(i \in R | \exists i \in R \cup O, X_i = x) = \pi_R(x) / \pi_O(x).$$

$$P(i \in O | \exists i \in R \cup O, X_i = x) = \pi_O(x) / (1 - \pi_R(x))$$

Table 2 summarizes the notations for convenience, and Table 1 illustrates the type of data considered.

²Also named sampling propensity score in Tipton (2013).

Table 1: Illustration of data structure of RCT data (Set) and observational data (Set) with covariates X, trial eligibility S, binary treatment A and outcome Y . Left: with observed outcomes, Right: with potential outcomes. Note that the S covariate can be either 0 or 1 in the observational data set (while usually unknown from the raw data set in the non-nested design), and is always equals to 1 for observations in the RCT. In the nested design (cf. Section D), S takes only value 0 in the observational data set.

	S	Set	Covariates			Treatment	Outcome	S	Set	Covariates			Treatment	Outcome(s)	
			X1	X2	X3	A	Y			X1	X2	X3	A	Y (0)	Y (1)
1	1	R	1.1	20		1	1	1	R	1.1	20	1	NA	1	
	1	R R		F		0	1	1	R R		F	0	1	NA	
n	1	O O-6	45			1	0	1	O O-6	45		1	NA	1	
n + 1	0	O O		F		0	O O		F	
	0		0	15		0	1	0		0	15	0	1	NA	
n + m	1			M		1	1	1			M	1	NA	1	
	0		...			0	0	0		...		0	0	NA	
			-2	52						-2	52				
				M							M				

$\tau(x)$ Conditional average treatment effect (CATE) defined as $\tau(x) = E[Y(1) - Y(0) | X = x]$ $\tau_1(x)$

Trial conditional average treatment effect defined as $\tau_1(x) = E[Y(1) - Y(0) | X = x, S = 1]$

$e(x)$ Propensity score defined as $e(x) = P(A = 1 | X = x)$

$e_1(x)$ Propensity score in the trial defined as $e_1(x) = P(A = 1 | X = x, S = 1)$, known by design

$\mu_a(x)$ Outcome mean defined as $\mu_a(x) = E[Y(a) | X = x]$ for $a = 0, 1$

$\mu_{a,1}(x)$ Outcome mean in the trial defined as $\mu_{a,1}(x) = E[Y(a) | X = x, S = 1]$ for $a = 0, 1$

$\pi_S(x)$ Selection score defined as $\pi_S(x) = P(S = 1 | X = x)$ $f(X)$ Covariates distribution in the target population

$f(X|S = 1)$ Covariates distribution conditional to trial-eligible individuals ($S = 1$)

Study designs; nested or not

It is important to characterize the study design because the identifiability conditions and therefore the estimators depend on and differ over the designs. Following ? and ?, the study design to obtain the trial and observational samples can be categorized into two types: nested study designs and non-nested study designs as illustrated on Figure 1. This categorization is similar to the classic one

in survey sampling with multiple datasets. This paper focuses on the non-nested design in the main text but we detail identifiability and estimators for the nested case in the Appendix D.

Non-nested trial design involves separate sampling mechanisms for the RCT and the observational samples. The trial sample and the observational sample are obtained separately from the target population(s). Here, we do not limit the two underlying populations for the trial and observational samples to be the same, but we assume that the target populations follow the same superpopulation model. For example, the trial study and the observational study are conducted by different researchers in different times or regions - with small time-specific or regional effects so that the underlying study populations are assumed to follow the same distribution. Note the difference between S and the sets \mathcal{S} and \mathcal{O} , where in the observational sample we can have both $S = 1$ and $S = 0$ (Figure 1). In this review, we consider the case where the observational data set is a random sample i.i.d from the target population. The medical application that will be presented in Section 7 corresponds to the non-nested design framework.

Nested trial design involves a two-stage sampling mechanism. First, a large sample is selected from the target population, and then the trial sample is selected from and nested in this sample. The rest of the sample constitutes the observational study. It corresponds to a real medical situation, such as designs for a pragmatic trial embedded in a broader health system. For example, in the Women Health Initiative (WHI), after the end of the initial trial period, a cohort of study participants are followed to measure their long-term outcomes. Olschewski and Scheurlen (1985) introduce the

comprehensive cohort study (CCS) design for evaluating competing treatments in which clinically eligible participants are first asked to enroll in a randomized trial and, if they refuse, are then asked to enroll in a parallel observational study in which they can choose treatment according to their own preference, leading to the observational data. Note that in this design, even the causal quantity of interest can be different from the non-nested design, as we may want to transport $\tau_1(x)$ in the observational population such that the causal quantity of interest is $E[Y(1) - Y(0) | S = 0]$ rather than $E[Y(1) - Y(0)]$ in the non-nested design.

When observational data have no treatment and outcome information

We start by considering the case where only the distribution of the covariates from the observational study is available or used. Note that observational data is a random sample from the target population.

Assumptions needed to identify the ATE on the target population

A fundamental problem in causal inference is that we can observe at most one of the potential outcomes for an individual subject. In order to identify the ATE from RCT and observational covariate data, we require some of the following assumptions.

Internal validity of the RCT

Assumption 3.1 (Consistency) $Y = A Y(1) + (1 - A) Y(0)$.

Nested

Non-Nested Design




Figure 1: Schematics of the nested (left) and non-nested (right) designs.

Assumption 3.1 implies that the observed outcome is the potential outcome under the actual as- signed

treatment.

Assumption 3.2 (Randomization) $Y(a) \perp A \mid (X, S = 1)$ for all X and $a = 0, 1$.

Assumption 3.2 corresponds to internal validity. It holds by design in a completely randomized experiment, where the treatment is independent of all the potential outcomes and covariates, i.e., $(Y(0), Y(1)) \perp A \mid S = 1$. It also holds by design in a stratified randomized trial based on a discrete X , where the treatment is independent of all the potential outcomes within each stratum of X : $Y(a) \perp A \mid (X, S = 1)$. The more general case of conditional randomization is kept.

In addition, in an RCT, it is common that the probability of treatment assignment (also called the propensity score) $e1(x)$ is known. In a complete randomized trial, the propensity score is fixed as a constant, e.g., $e1(x) = 0.5$ for all x .

Generalizability of the RCT to the target population

Different assumptions on the generalizability of the RCT to the target population are proposed in the literature, ranging from weak to stringent conditions. We now describe these assumptions and their implications.

Assumption 3.3 (Transportability of the CATE) $\tau1(x) = \tau(x)$ for all x .

Assumption 3.3 requires that the CATE function is transportable from the RCT to the target population, which is plausible if X captures all the treatment effect modifiers and there is no trial

encouragement. It means that the invitation to participate in the trial and trial participation itself do not affect the outcome except through treatment assignment (?).

Assumption 3.4 (Mean exchangeability over treatment assignment and trial participation)

$E[Y(a) | X = x, S = 1, A = a] = E[Y(a) | X = x, S = 1]$ (Dahabreh et al., 2019) as well as $E[Y(a) | X = x, S = 1] = E[Y(a) | X = x]$ for each x and $a = 0, 1$.

Assumption 3.4 means exchangeability over treatment assignment in the trial given covariates is expected to hold by design in the RCT.

Assumption 3.5 (Ignorability assumption on trial participation) $Y(0), Y(1) \perp\!\!\!\perp S \mid X$. (Stuart et al., 2011; Buchanan et al., 2018)

Assumption 3.5 means that being eligible to the RCT does not affect the potential outcomes conditionally on the covariates X . In other words, it means that there are no unmeasured variables associated with the trial sample selection and the treatment effect. This is the parallel with the ignorability assumption on treatment assignment in causal inference with observational data (see 4.1), but with the sample selection.

It is worth discussing the relationships among Assumptions 3.3 – 3.5, ranging from weak to strong conditions. Assumption 3.3, transportability of the CATE, is implied by, but does not imply, the stronger conditions in Assumption 3.4. Assumption 3.4, mean exchangeability over treatment assignment, is implied by, but does not imply, the stronger conditions $Y(a) \perp\!\!\!\perp A \mid X, S = 1$ implied by Assumption 3.2. In the same way, mean exchangeability over trial participation, also known as mean generalizability (from trial participants to the target population), is implied by, but does not imply, the stronger condition $Y(a) \perp\!\!\!\perp S \mid X$ in Assumption 3.5 (participation in the RCT is randomized within levels of X). Note that for binary S , mean exchangeability over trial participation implies the mean transportability condition $E[Y(a) | X = x, S = 1] = E[Y(a) | X = x, S = 0]$ in Assumption 3.3, for all x such that $P(S = 0 | X = x) > 0$.

x with probability 1, $\pi_S(x) \geq c > 0$; and $0 < P(A = a | X = x, S = 1) < 1$ for all a and for all x such that $P(S = 1 | X = x) > 0$. Assumption 3.6 (Positivity of trial participation) There exists a constant c such that for all

Assumption 3.6 means that we require adequate overlap of the covariate distribution between the trial sample and the target population (in other words, all members of the target population have nonzero probability of being selected into the trial), and also between the treatment groups over the trial sample. The positivity of treatment assignment in the trial given covariates, related to the assumption required for causal inference in confounded settings, is expected to hold by design in the RCT.

Towards identification formula

Inverse probability of sampling weighting (IPSW) The IPSW approach can be seen as the counterpart of inverse propensity weighting (IPW) methods to estimate the ATE from observational studies to control for confounding (see Appendix B for details). Based on the identification formula (Equation 1), the IPSW estimator of the ATE is defined as the weighted difference of average outcomes between the treated and control group in the trial. The observations are weighted by the inverse odds ratio $1/\alpha(x) = \pi_O(x)/\pi_R(x)$ to account for the shift of the covariate distribution from the RCT sample to the target population. The larger π_R , the smaller the weight of the observation. The shape of the IPSW estimator is slightly different from the shape of the IPW estimator. In the latter, each observation is weighted by the inverse of the probability to be treated whereas in the former it is by the inverse of the odds ratio of the probability to be in the trial sample. This is due to the non-nested sampling design (see the estimator for the nested design (S3)), as mentioned by Kern et al. (2016) and Nguyen et al. (2018). The IPSW estimator can be written as follows:

$$\hat{\alpha}^{IPSW} = \frac{\sum_{i=1}^n Y_i (2A_i - 1)}{\sum_{i=1}^n \frac{1}{\alpha(X_i)}} \quad (3)$$

$$= \frac{\sum_{i=1}^n Y_i (2A_i - 1)}{\sum_{i=1}^n \frac{1}{\alpha(X_i)}}$$

$$\hat{\alpha}^{IPSW} = \frac{\sum_{i=1}^n 2Y_i (2A_i - 1)}{\sum_{i=1}^n \frac{1}{\alpha(X_i)}}$$

$$\hat{\alpha}^{IPSW} = \frac{\sum_{i=1}^n 2Y_i (2A_i - 1)}{\sum_{i=1}^n \frac{1}{\alpha(X_i)}}$$

$$\hat{\alpha}^{IPSW} = \frac{\sum_{i=1}^n 2Y_i (2A_i - 1)}{\sum_{i=1}^n \frac{1}{\alpha(X_i)}}$$

The IPSW estimator is consistent when the quantity α is consistently estimated by $\hat{\alpha}$. The most common method for estimating the selection score is to define it as $\hat{\alpha}(x) = \hat{\pi}_R(x)/(1 - \hat{\pi}_R(x))$, where π_R is estimated by logistic regression trained to discriminate RCT from observational samples (Stuart, 2010), while recent works also use other methods such as random forest and GBM (Kern et al., 2016). Similar to IPW estimators, IPSW estimators are known to be highly unstable, especially when the selection scores are extreme. It happens when the trial study contains units with very small probabilities of being in the trial. Normalized weights can be used to overcome this issue (?). Still, the major challenge is that IPSW estimators require a correct model specification of the selection score. Avoiding this problem requires either very strong domain expertise or turning to doubly robust methods (Section 3.2.4). Finally, Dahabreh et al. (2019) propose the use of sandwich- type variance estimators (for both nested and non-nested design) or non-parametric bootstrap approaches, and note that the latter may be preferred in practice.

Stratification The stratification approach – also called subclassification – is introduced by Cochran (1968), and further detailed by Stuart et al. (2011), Tipton (2013), and O’Muircheartaigh and Hedges (2014). It is proposed as a solution to mitigate the dangers of extreme weights in the IPSW formula. The principle is to form L strata based on the covariate values via the selection score, which in practice consists in grouping observations for which π are similar. Then, in each stratum l , the average treatment effect is estimated as $Y(1)_l - Y(0)_l$ where $Y(a)_l$ denotes the average value of the outcome for units with treatment a in stratum l in the RCT. Finally, the ATE estimator is the weighted sum of the difference between means in each stratum:

$$\hat{\tau} = \sum_{l=1}^L \pi_l [Y(1)_l - Y(0)_l],$$

where m_l/m is the proportion of population cases in the stratum l in the observational study. Kang et al. (2007) assess performance of the stratification as opposed to the IPSW, and show that stratification is less effective than IPSW at removing bias, but that IPSW struggle more than stratification when the selection scores are small.

